Information  X 
Enter a valid email address

RedxPhar (REDX)

Related News

23-Jun-2022 11:29 AM

IN BRIEF: Redx Pharma narrows half-year loss as pipeline progresses

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - In the half year ended March 31, pretax loss narrows to £9.7 million from £12.7 million year-on-year.
15-Jun-2022 10:24 AM

Redx Pharma rises on FDA clearance for solid tumour treatment JZP815

Redx Pharma PLC on Wednesday said the US Food & Drug Administration has cleared the investigational new drug application for JZP815, a pan-RAF inhibitor for the treatment of solid tumours and haematological malignancies. The clearance pave
18-May-2022 07:37 PM

IN BRIEF: Redx Pharma to raise £30 million to fund pipelines

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Proposes to raise £30 million through a placing to institutional investors of shares at a price of 59 penc
08-Apr-2022 07:41 PM

IN BRIEF: Redx Pharma notes ‘encouraging’ RXC004 data in cancer

Redx Pharma PLC - Macclesfield, England-based clinical-stage biotechnology company focused on the treatment of cancer and fibrotic disease - Notes ‘encouraging’ preclincal data for RXC004 as a targeted therapy for Wnt-ligand driven cancer.
30-Mar-2022 12:05 PM

IN BRIEF: Redx Pharma to start new Crohn's disease study in late 2023

Redx Pharma PLC - Cheshire-based cancer and fibrosis drug developer - Announces end of 2023 as start of phase 1 studies for its Crohn's disease clinical development candidate RXC008. The inhibitor is designed to act exclusively in the gastrointest
10-Mar-2022 08:31 PM

IN BRIEF: Redx Pharma notes encouraging safety data for RXC007

(Alliance News) Redx Pharma PLC - Cheshire-based cancer and fibrosis drug developer - Says phase 1 data presented at Virtual Interstitial Lung Disease Drug Development summit shows novel anti-fibrotic drug candidate, RXC007, possesses excellent safety
07-Jun-2021 09:41 AM

Redx Pharma losses deepen as develops cancer, fibrosis treatments

Pharmaceutical company Redx Pharma posted a deeper annual loss as it continued to develop potential treatments for cancer and fibrosis. Pre-tax losses for the year through March amounted to £12.7 million, compared to year-on-year losses of £4
02-Mar-2021 01:37 PM

Redx Pharma begins just for US CFO

Drug discovery and development company, Redx Pharma has initiated its search for a US-based chief financial officer following its annual general meeting held on March 2, 2021. James Mead will continue in his role as chief financial officer until a new a
27-Jan-2021 08:52 AM

Redx Pharma losses deepen as development spending offsets rising sales

Oncology and fibrosis focused Redx Pharma reported a deeper annual loss after rising revenue was offset by higher spending on its development pipeline. Pre-tax losses for the year through September amounted to £9.2 million, compared to year-on-year
11-Mar-2020 08:11 AM

Redx Pharma posts annual loss as it develops drug candidates

Pharmaceutical group Redx Pharma posted a full-year loss as it continued to develop its oncology and fibrosis treatment candidates. Pre-tax losses for the year through September amounted to £6.3m, compared to losses of £10.1m on-year. Revenu
31-Dec-2019 08:29 AM

Redx Pharma in discussions over possible bid

Drug discovery and development firm Redx Pharma said it is in discussions over a possible cash offer from an investor group led by biotech industry figure Sam Waksal. The company said the announcement did not amount to a firm intention to make an offer a
19-Nov-2018 08:17 AM

Redx Pharma swings to loss; to kick off new clinical trial in 2019

Oncology and fibrosis-focused drug developer Redx Pharma swung to an annual loss after emerging from administration in November and slashing its headcount. The company also announced that it had appointed James Mead as its chief financial officer, replac
30-May-2018 08:39 AM

Redx Pharma losses halve after exiting adminstration

Cancer and fibrosis drug development group Redx Pharma said its first-half losses halved after it exited administration in November and re-focused its R&D efforts to cut costs. Pre-tax losses amounted to £4.9m, compared to £11.0m of red ink a
20-Dec-2017 08:16 AM

Redx Pharma swings from loss to profit

Redx Pharma reported a profit of £1.528m (2016: loss £15,521m) in the year ended 30 September 2017. In an extraordinary 12 months, the company entered Administration in May 2017 and then, post period in November 2017, successfully exited as a
03-Nov-2017 03:00 PM

Redx Pharma, Redx Oncology resume trading

Redx Pharma and Redx Oncology have confirmed that they have both now resumed trading after joint administrators filed their Final Report in the administrations of the Companies at Court and with the Registrar of Companies. The Board said it expects to ma
20-Apr-2017 01:22 PM

All resolutions passed at Redx AGM

Redx Pharma has confirmed that all resolutions were passed by shareholders at today's Annual General Meeting. At 1:22pm: (LON:REDX) Redx Pharma Plc Ord 1p share price was +0.13p at 36p Story provided by StockMarketWire.com...
20-Apr-2017 09:06 AM

Redx Pharma appoints Iain Ross as chairman

Redx Pharma has appointed Iain Ross as chairman of its Board of Directors and as a Non-Executive Director of the Company, effective from May 1. At 9:06am: (LON:REDX) Redx Pharma Plc Ord 1p share price was +0.13p at 36p Story provided by StockMarket
28-Feb-2017 01:03 PM

Redx shareholders approve equity issue

Redx has announced that, at the General Meeting held earlier today, all resolutions proposed were passed and as a result 26,779,958 new ordinary shares of 1p each will be admitted to trading on 1 March 2017. At 1:03pm: (LON:REDX) Redx Pharma Plc Ord 1
13-Apr-2016 12:12 PM

Redx shareholders approve equity issue

Redx has announced that all resolutions proposed at today's General Meeting were duly passed. As a result, 285,714 and 22,105,518 ordinary shares of 1 pence each in the Company will be admitted to trading on 14 and 15 April, respectively. At 12:
01-Oct-2015 07:27 AM

Redx's H2

Redx Pharma has continued to make good progress over H2 and noted the group's expenditure remains in line with budgets. FY total operating income is anticipated to be £2.8m, from £2.0m in the six months to March 31. FY cash balance is seen at abo

a d v e r t i s e m e n t